Toribio-Castelló Sofía, Castaño Sandra, Villaverde-Ramiro Ángela, Such Esperanza, Arnán Montserrat, Solé Francesc, Díaz-Beyá Marina, Díez-Campelo María, Del Rey Mónica, González Teresa, Hernández-Rivas Jesús María
IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, 37007 Salamanca, Spain.
Department of Hematology, University Hospital of Salamanca, 37007 Salamanca, Spain.
Cancers (Basel). 2023 Jul 27;15(15):3822. doi: 10.3390/cancers15153822.
Trisomy 8 (+8) is the most frequent trisomy in myelodysplastic syndromes (MDS) and is associated with clinical heterogeneity and intermediate cytogenetic risk when found in isolation. The presence of gene mutations in this group of patients and the prognostic significance has not been extensively analyzed. Targeted deep sequencing was performed in a cohort of 79 MDS patients showing isolated +8. The most frequently mutated genes were: (38%), (34.2%), (29.1%) and (26.6%). The mutational profile identified a high-risk subgroup with mutations in , and/or , resulting in shorter time to acute myeloid leukemia progression (14 months while not reached in patients without these mutations, < 0.0001) and shorter overall survival (23.7 vs. 46.3 months, = 0.001). Multivariate analyses revealed the presence of mutations in these genes as an independent prognostic factor in MDS showing +8 isolated (HR: 3.1; < 0.01). Moreover, 39.5% and 15.4% of patients classified as low/intermediate risk by the IPSS-R and IPSS-M, respectively, were re-stratified as a high-risk subgroup based on the mutational status of , and . Results were validated in an external cohort ( = 2494). In summary, this study validates the prognosis significance of somatic mutations shown in IPSS-M and adds as an important mutated gene to consider in this specific subgroup of patients. The mutational profile in isolated +8 MDS patients could, therefore, offer new insights for the correct management of patients with a higher risk of leukemic transformation.
8号染色体三体(+8)是骨髓增生异常综合征(MDS)中最常见的三体,单独出现时与临床异质性及中等细胞遗传学风险相关。该组患者中基因突变的存在及其预后意义尚未得到广泛分析。对79例显示孤立+8的MDS患者进行了靶向深度测序。最常发生突变的基因是:(38%)、(34.2%)、(29.1%)和(26.6%)。突变谱确定了一个高危亚组,其、和/或发生突变,导致急性髓系白血病进展时间缩短(14个月,而无这些突变的患者未达到此时间,<0.0001),总生存期缩短(23.7个月对46.3个月,=0.001)。多变量分析显示,这些基因中的突变是孤立显示+8的MDS的独立预后因素(HR:3.1;<0.01)。此外,根据IPSS-R和IPSS-M分别归类为低/中危的患者中,39.5%和15.4%根据、和的突变状态重新分层为高危亚组。结果在一个外部队列(=2494)中得到验证。总之,本研究验证了IPSS-M中显示的体细胞突变的预后意义,并将作为该特定患者亚组中一个重要的突变基因加以考虑。因此,孤立+8 MDS患者的突变谱可为白血病转化风险较高患者的正确管理提供新的见解。